☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC reject melatonin

The Midlands Therapeutics Review and Advisory Committee has issued advice for doctors in the West Midlands that melatonin 2mg controlled release (Circadin®) cannot be recommended due to inadequate evidence of efficacy or safety.

The review identified two randomised controlled trials that compared melatonin to placebo. No trials were identified that used active comparators.

These two trials collected primary data on subjective improvements in sleep scored using the Leeds Sleep Evaluation Questionnaire. Duration of sleep and latency of sleep were analysed as secondary outcomes.

Overall, the results did show some subjective benefit but the effect size was small. Clinically significant improvements in sleep scores were apparent from 14% of placebo users compared to 25% of melatonin users. It was also found that participants in the active treatment arm did not sleep for longer but did get to sleep 9 minutes earlier than patients taking placebo; this difference was statistically significant but the clinical significance remains in doubt.

Action: Clinicians will find that this review is a useful summary of the available data. This drug should not be in routine use due to the lack of comparative data versus existing treatments.

Share 'MTRAC reject melatonin' on Email Share 'MTRAC reject melatonin' on Delicious Share 'MTRAC reject melatonin' on Digg Share 'MTRAC reject melatonin' on Facebook Share 'MTRAC reject melatonin' on reddit Share 'MTRAC reject melatonin' on Twitter

atomic-wealth

No Comments to “MTRAC reject melatonin”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

vipers